Ropivacaine Hydrochloride

Local Anesthetic Amide-type local anesthetic

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog Epidural 0.5-1 mg/kg (0.5% solution) Single dose Duration: 2-4 hours
Notes: Dilute with preservative-free saline to achieve appropriate volume. Use lower doses for analgesia, higher for motor block.
Dog Peripheral nerve block 1-2 mg/kg (0.2-0.5% solution) Single dose Duration: 4-8 hours
Notes: Maximum total dose should not exceed 3 mg/kg.
Cat Epidural 0.5-1 mg/kg (0.5% solution) Single dose Duration: 2-4 hours
Notes: Use with caution in cats; lower doses may be sufficient.
Cat Peripheral nerve block 1-2 mg/kg (0.2-0.5% solution) Single dose Duration: 4-8 hours
Notes: Maximum total dose should not exceed 2 mg/kg.
Horse Epidural 0.05-0.1 mg/kg (0.5% solution) Single dose Duration: 2-3 hours
Notes: Administer slowly; monitor for ataxia.
Horse Peripheral nerve block 2-4 mL of 0.5% solution per site Single dose Duration: 2-4 hours
Notes: Adjust volume based on procedure.
Cattle Epidural 0.05-0.1 mg/kg (0.5% solution) Single dose Duration: 2-3 hours
Notes: For obstetrical procedures; monitor for recumbency.
Cattle Peripheral nerve block 5-10 mL of 0.5% solution per site Single dose Duration: 2-4 hours
Notes: Common for cornual nerve block.
Small Ruminants Epidural 0.05-0.1 mg/kg (0.5% solution) Single dose Duration: 2-3 hours
Notes: Use with caution; monitor for respiratory depression.
Rabbit Epidural 0.5-1 mg/kg (0.5% solution) Single dose Duration: 2-4 hours
Notes: Small volumes; use preservative-free solutions.
Bird/Poultry Infiltration 1-2 mg/kg (0.2-0.5% solution) Single dose Duration: 1-2 hours
Notes: Use with caution; birds are sensitive to local anesthetics.

Clinical Indications & Species Uses

General Indications
  • Local and regional anesthesia
  • Epidural analgesia
  • Peripheral nerve blocks
  • Infiltration anesthesia
  • Postoperative pain management
Dog (Canine)
  • Local and regional anesthesia
  • Epidural analgesia for surgery or obstetrics
  • Peripheral nerve blocks (e.g., brachial plexus, femoral-sciatic)
  • Infiltration anesthesia
  • Postoperative pain management
Cat (Feline)
  • Local and regional anesthesia
  • Epidural analgesia for surgery or obstetrics
  • Peripheral nerve blocks
  • Infiltration anesthesia
  • Postoperative pain management
Horse (Equine)
  • Epidural anesthesia for standing surgery
  • Peripheral nerve blocks (e.g., palmar digital, abaxial sesamoid)
  • Infiltration anesthesia
  • Postoperative pain management
Cattle (Bovine)
  • Epidural anesthesia for obstetrical procedures
  • Peripheral nerve blocks (e.g., cornual, paravertebral)
  • Infiltration anesthesia
  • Postoperative pain management
Small Ruminants (Sheep / Goat)
  • Epidural anesthesia for obstetrical procedures
  • Peripheral nerve blocks
  • Infiltration anesthesia
Rabbit & Small Mammals
  • Local and regional anesthesia
  • Epidural analgesia
  • Peripheral nerve blocks
  • Infiltration anesthesia
Avian & Poultry
  • Local anesthesia for minor procedures
  • Infiltration anesthesia
Exotic & Other Species
  • Local anesthesia in small mammals (e.g., ferrets, guinea pigs)
  • Epidural analgesia in some exotic species

Pharmacology & Mechanism of Action

Drug Class: Local Anesthetic | Pharmacological Group: Amide-type local anesthetic

Mechanism of Action: Ropivacaine is a long-acting amide local anesthetic that reversibly blocks sodium channels in nerve fibers, thereby inhibiting the propagation of action potentials. It binds to the intracellular portion of voltage-gated sodium channels, preventing the influx of sodium ions during depolarization. This blockade is more pronounced in small-diameter nerve fibers (A-delta and C fibers) responsible for pain transmission, while motor fibers (A-alpha) are less affected, resulting in differential sensory and motor blockade. The drug also exhibits anti-inflammatory properties by inhibiting neutrophil activation and reducing the release of inflammatory mediators.

Pharmacodynamics: Ropivacaine produces a concentration-dependent blockade of sensory, motor, and autonomic nerve fibers. At lower concentrations, it provides analgesia with minimal motor blockade, making it suitable for pain management. At higher concentrations, it produces complete motor blockade. The onset of action is relatively rapid (within 5-15 minutes for epidural administration), and the duration of action is long (2-6 hours depending on dose and route). Ropivacaine is less cardiotoxic and neurotoxic than bupivacaine, likely due to its lower lipid solubility and stereospecificity (S-enantiomer). It also has vasoconstrictive properties at low concentrations, which may prolong its local effect.

⚡ Pharmacokinetics Summary

Absorption: Ropivacaine is well absorbed from the site of administration, with systemic absorption dependent on the dose, route, and vascularity of the injection site. Peak plasma concentrations occur within 10-30 minutes after epidural or peripheral nerve block administration. Absorption is slower from less vascularized tissues.
Distribution: Ropivacaine is widely distributed in the body, with a volume of distribution of approximately 40-60 L in humans. It is extensively bound to plasma proteins, primarily alpha-1-acid glycoprotein (AAG), with a protein binding of about 94%. In veterinary species, protein binding may vary; for example, in dogs it is approximately 90%.
Metabolism: Ropivacaine is extensively metabolized in the liver, primarily by cytochrome P450 enzymes, mainly CYP1A2 and CYP3A4. The major metabolite is 3-hydroxyropivacaine, which has minimal local anesthetic activity. Metabolism is rapid, and hepatic clearance is high.
Excretion: Ropivacaine and its metabolites are excreted primarily in the urine. Less than 1% of the drug is excreted unchanged. The elimination half-life is approximately 2-4 hours in humans, but in veterinary species it may vary; for example, in dogs it is about 1-2 hours, and in horses it is about 1.5 hours.
Half-Life: Dogs: 1-2 hours; Cats: 1-2 hours; Horses: 1.5 hours; Cattle: 1-2 hours (estimated); Rabbits: 1-2 hours (estimated)
Bioavailability: Systemic bioavailability is high after epidural or regional administration due to absorption; oral bioavailability is low due to first-pass metabolism (not used orally).
Protein Binding: Approximately 90-94% bound to plasma proteins, primarily alpha-1-acid glycoprotein.

Available Formulations & Strengths

Injectable Solution 0.2% (2 mg/mL), 0.5% (5 mg/mL), 0.75% (7.5 mg/mL), 1% (10 mg/mL) (Epidural, infiltration, peripheral nerve block)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to ropivacaine or other amide local anesthetics
  • Severe hypotension or cardiogenic shock
  • Infection at the injection site
  • Coagulopathy or bleeding disorders (for epidural use)
  • Severe hepatic impairment (due to reduced metabolism)
  • Use in pregnant animals unless clearly necessary (risk of fetal bradycardia)
Warnings & Clinical Precautions:
  • Use with caution in animals with cardiovascular disease, as ropivacaine can cause myocardial depression and arrhythmias.
  • Epidural administration may cause hypotension and respiratory depression; monitor vital signs closely.
  • Do not use solutions containing preservatives for epidural or intrathecal administration.
  • Accidental intravascular injection can cause systemic toxicity; aspirate before injection.
  • Use the lowest effective dose to minimize risk of toxicity.
  • In food animals, observe withdrawal times; extra-label use requires veterinary oversight.
  • In horses, avoid use in animals with neurological deficits.
  • In small animals, use with caution in very young or geriatric patients.

Adverse Effects & Reactions

Common:

  • Transient hypotension
  • Nausea (in humans; may occur in animals)
  • Temporary motor weakness
  • Urinary retention (with epidural use)
  • Local tissue irritation at injection site

Serious / Severe:

  • Cardiac arrhythmias (e.g., ventricular tachycardia, fibrillation)
  • Cardiac arrest
  • Seizures
  • Central nervous system depression
  • Respiratory depression
  • Methemoglobinemia (rare)
  • Allergic reactions (anaphylaxis)

Rare:

  • Neurological damage (with epidural use)
  • Cauda equina syndrome
  • Arachnoiditis
  • Peripheral neuropathy
  • Hepatotoxicity (with overdose)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other local anesthetics (e.g., lidocaine, bupivacaine) Additive systemic toxicity, especially cardiovascular and CNS effects. High
Antiarrhythmic drugs (e.g., amiodarone, sotalol) Increased risk of cardiac toxicity. High
Beta-blockers Reduced hepatic clearance of ropivacaine, increasing risk of toxicity. Moderate
CYP1A2 inhibitors (e.g., fluoroquinolones, cimetidine) Decreased metabolism of ropivacaine, leading to increased plasma levels. Moderate
CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) Potential increase in ropivacaine levels. Moderate
Vasoconstrictors (e.g., epinephrine) May prolong anesthetic effect but increase risk of systemic toxicity if injected intravascularly. Mild

Overdose & Toxicity Management

Signs of Toxicity:

  • Central nervous system excitation (restlessness, tremors, seizures)
  • Central nervous system depression (drowsiness, coma)
  • Cardiovascular effects (hypotension, bradycardia, arrhythmias, cardiac arrest)
  • Respiratory depression
  • Methemoglobinemia (cyanosis)

Emergency Treatment Protocol: Immediately discontinue administration. Ensure airway patency and provide oxygen. Treat seizures with benzodiazepines (e.g., diazepam) or barbiturates. For cardiovascular depression, administer intravenous fluids and vasopressors (e.g., epinephrine, norepinephrine). In severe cases, lipid emulsion therapy (Intralipid 20%) may be used to sequester the drug. Monitor cardiac function and provide supportive care.

Food Animal Withdrawal Times

🥩 Meat: 7 days🥛 Milk: 3 days

Withdrawal times are not established for ropivacaine in food animals; these are estimates based on pharmacokinetic data. Consult regulatory authorities for specific guidance. Extra-label use requires extended withdrawal periods.

Storage, Handling & Regulatory Information

Storage Temperature: Store at controlled room temperature 20-25°C (68-77°F), excursions permitted between 15-30°C (59-86°F).

Handling & Special Conditions: Protect from freezing. Keep in tightly closed container. Do not use if solution is discolored or contains particulate matter.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not FDA-approved for veterinary use; approved for human use.

Extra-Label (Off-Label) Use: In the US, ropivacaine is not FDA-approved for veterinary use; it is used extra-label under the Animal Medicinal Drug Use Clarification Act (AMDUCA). Extra-label use requires a valid veterinarian-client-patient relationship and must follow withdrawal time guidelines.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Ropivacaine is a valuable local anesthetic in veterinary practice due to its favorable safety profile compared to bupivacaine, with less motor blockade at lower concentrations and reduced cardiotoxicity. It is particularly useful for epidural analgesia in dogs, cats, and horses, providing long-lasting pain relief with minimal motor impairment. For peripheral nerve blocks, it offers effective anesthesia for surgical procedures. In food animals, its use is limited by lack of established withdrawal times, but it can be used with appropriate precautions. Always calculate the maximum safe dose based on body weight and use the lowest effective concentration. Monitor for signs of systemic toxicity, especially during epidural or large-volume injections. In small exotic species, use with extreme caution due to limited safety data. Ropivacaine should be stored properly and used only by trained professionals.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)